Literature DB >> 29253593

Tumor cell cholesterol depletion and V-ATPase inhibition as an inhibitory mechanism to prevent cell migration and invasiveness in melanoma.

Gildeíde Aparecida Costa1, Sávio Bastos de Souza1, Layz Ribeiro da Silva Teixeira2, Lev A Okorokov2, Andrea Cristina Vetö Arnholdt3, Anna L Okorokova-Façanha2, Arnoldo Rocha Façanha4.   

Abstract

BACKGROUND: V-ATPase interactions with cholesterol enriched membrane microdomains have been related to metastasis in a variety of cancers, but the underlying mechanism remains at its beginnings. It has recently been reported that the inhibition of this H+ pump affects cholesterol mobilization to the plasma membrane.
METHODS: Inhibition of melanoma cell migration and invasiveness was assessed by wound healing and Transwell assays in murine cell lines (B16F10 and Melan-A). V-ATPase activity was measured in vitro by ATP hydrolysis and H+ transport in membrane vesicles, and intact cell H+ fluxes were measured by using a non-invasive Scanning Ion-selective Electrode Technique (SIET).
RESULTS: Cholesterol depletion by 5mM MβCD was found to be inhibitory to the hydrolytic and H+ pumping activities of the V-ATPase of melanoma cell lines, as well as to the migration and invasiveness capacities of these cells. Nearly the same effects were obtained using concanamycin A, a specific inhibitor of V-ATPase, which also promoted a decrease of the H+ efflux in live cells at the same extent of MβCD.
CONCLUSIONS: We found that cholesterol depletion significantly affects the V-ATPase activity and the initial metastatic processes following a profile similar to those observed in the presence of the V-ATPase specific inhibitor, concanamycin. GENERAL SIGNIFICANCE: The results shed new light on the functional role of the interactions between V-ATPases and cholesterol-enriched microdomains of cell membranes that contribute with malignant phenotypes in melanoma.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Antimetastatic target; Cholesterol rafts; Proton pumps

Mesh:

Substances:

Year:  2017        PMID: 29253593     DOI: 10.1016/j.bbagen.2017.12.006

Source DB:  PubMed          Journal:  Biochim Biophys Acta Gen Subj        ISSN: 0304-4165            Impact factor:   3.770


  7 in total

1.  Copper blocks V-ATPase activity and SNARE complex formation to inhibit yeast vacuole fusion.

Authors:  Gregory E Miner; Katherine D Sullivan; Chi Zhang; Logan R Hurst; Matthew L Starr; David A Rivera-Kohr; Brandon C Jones; Annie Guo; Rutilio A Fratti
Journal:  Traffic       Date:  2019-09-02       Impact factor: 6.215

Review 2.  The Lysosome in Malignant Melanoma: Biology, Function and Therapeutic Applications.

Authors:  Chia-Hsin Hsu; Keng-Jung Lee; Yi-Han Chiu; Kuo-Ching Huang; Guo-Shou Wang; Lei-Po Chen; Kuang-Wen Liao; Chen-Si Lin
Journal:  Cells       Date:  2022-04-29       Impact factor: 7.666

3.  A novel long-sustaining system of apatinib for long-term inhibition of the proliferation of hepatocellular carcinoma cells.

Authors:  Yanli Wang; Zigui Tang
Journal:  Onco Targets Ther       Date:  2018-11-29       Impact factor: 4.147

4.  Silencing the expression of copine-III enhances the sensitivity of hepatocellular carcinoma cells to the molecular targeted agent sorafenib.

Authors:  Zhuo Chen; Zhengkui Jiang; Wenzhou Zhang; Baoxia He
Journal:  Cancer Manag Res       Date:  2018-08-29       Impact factor: 3.989

Review 5.  V-ATPases and osteoclasts: ambiguous future of V-ATPases inhibitors in osteoporosis.

Authors:  Xiaohong Duan; Shaoqing Yang; Lei Zhang; Tielin Yang
Journal:  Theranostics       Date:  2018-10-26       Impact factor: 11.556

6.  MYC Enhances Cholesterol Biosynthesis and Supports Cell Proliferation Through SQLE.

Authors:  Fan Yang; Junjie Kou; Zizhao Liu; Wei Li; Wenjing Du
Journal:  Front Cell Dev Biol       Date:  2021-03-11

Review 7.  Lipid metabolic Reprogramming: Role in Melanoma Progression and Therapeutic Perspectives.

Authors:  Laurence Pellerin; Lorry Carrié; Carine Dufau; Laurence Nieto; Bruno Ségui; Thierry Levade; Joëlle Riond; Nathalie Andrieu-Abadie
Journal:  Cancers (Basel)       Date:  2020-10-27       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.